{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-028123","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.519681+00:00","generated_at":"2026-05-26T16:46:53.496283+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Solid Biosciences reports 110% avg microdystrophin expression from SGT-003 Phase 1/2 trial","bullets":["First three participants showed average 110% microdystrophin expression by western blot and 78% dystrophin-positive fibers at Day 90.","Mean reductions in muscle injury biomarkers: CK -57%, AST -45%, ALT -54%, LDH -60% at Day 90.","Two participants at Day 180 showed mean LVEF increase of 8% from baseline; no serious adverse events or TMA observed.","Preliminary cash, cash equivalents and available-for-sale securities of ~$148.9M as of Dec 31, 2024.","Company plans mid-2025 FDA meeting to discuss accelerated approval for SGT-003; enrollment ongoing with 7th dosed Feb 17."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-028123","json":"https://secwatch.observer/filing/0001193125-25-028123.json","markdown":"https://secwatch.observer/filing/0001193125-25-028123.md","text":"https://secwatch.observer/filing/0001193125-25-028123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525028123/0001193125-25-028123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525028123/d913726d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:46:53.496283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}